Zisis, M.; Chondrogianni, M.E.; Androutsakos, T.; Rantos, I.; Oikonomou, E.; Chatzigeorgiou, A.; Kassi, E.
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules 2025, 15, 324.
https://doi.org/10.3390/biom15030324
AMA Style
Zisis M, Chondrogianni ME, Androutsakos T, Rantos I, Oikonomou E, Chatzigeorgiou A, Kassi E.
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules. 2025; 15(3):324.
https://doi.org/10.3390/biom15030324
Chicago/Turabian Style
Zisis, Marios, Maria Eleni Chondrogianni, Theodoros Androutsakos, Ilias Rantos, Evangelos Oikonomou, Antonios Chatzigeorgiou, and Eva Kassi.
2025. "Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment" Biomolecules 15, no. 3: 324.
https://doi.org/10.3390/biom15030324
APA Style
Zisis, M., Chondrogianni, M. E., Androutsakos, T., Rantos, I., Oikonomou, E., Chatzigeorgiou, A., & Kassi, E.
(2025). Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules, 15(3), 324.
https://doi.org/10.3390/biom15030324
